Related references
Note: Only part of the references are listed.Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Jeffrey S. Heier et al.
LANCET (2022)
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Chirag D. Jhaveri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Mohamed A. Hamid et al.
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS (2021)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease A Randomized Clinical Trial
Peter J. Kertes et al.
JAMA OPHTHALMOLOGY (2020)
Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
Hemal Mehta et al.
CLINICAL OPHTHALMOLOGY (2020)
SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States
Arshad M. Khanani et al.
OPHTHALMOLOGY RETINA (2020)
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Theodoros Empeslidis et al.
ADVANCES IN THERAPY (2019)
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective
Freekje van Asten et al.
PLOS ONE (2018)
Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
Ali Dirani et al.
CLINICAL OPHTHALMOLOGY (2018)
Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis
Seth R. Flaxman et al.
LANCET GLOBAL HEALTH (2017)
Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice
Raphaelle Despreaux et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2016)
Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015; 122: 146-52)
Robert L. Avery
OPHTHALMOLOGY (2016)
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Ursula Schmidt-Erfurth et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2016)
INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY
Valentina Sarao et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB Time Course and Drug Effects
Sophie De Massougnes et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis
Rishi P. Singh et al.
CLINICAL OPHTHALMOLOGY (2015)
Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010
Rupert R. A. Bourne et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison
Joao Pinheiro-Costa et al.
OPHTHALMOLOGICA (2014)
Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration
Joshua D. Stein et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
Helen A. Dakin et al.
BMJ OPEN (2014)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
Switching Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
Andrew P. Schachat
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Usha Chakravarthy et al.
LANCET (2013)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
Susanne Binder
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
